ArcherDX Blog



Mar
5
2019

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth


Feb
12
2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.


Jan
30
2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.


Jan
8
2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.


Dec
20
2018

How to decipher noisy regions with per-variant sensitivity detection

Background noise isn't static, so why should your sensitivity threshold be static? Traditional limit of detection measurements are based on static thresholds which average this noise, but Archer scientists have recently developed a method to model the noise at each base position requiring only a small set of samples. This method allows for position-specific sensitivity thresholds, termed 95 MDAF, which increases confidence in variant detection in noisy regions.


Oct
11
2018

Validation of the Archer FusionPlex Sarcoma kit

A paper published in The Journal for Molecular Diagnostics shows a direct comparison between the Archer FusionPlex Sarcoma panel and conventional methods for gene fusion detection, including fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR)


Oct
11
2018

Utility of Anchored Multiplex PCR for gene fusion detection®

Watch Dr. Cecilia Yeung's talk on using AMP™ technology for rapid identification of fusions in leukemias with Oxford Nanopore™ real-time sequencing from CGC 2018.


Oct
3
2018

Press release: Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

ArcherDX and Merck KGaA, Darmstadt, Germany have entered into an agreement to develop and commercialize a next generation sequencing (NGS)-based companion diagnostic (CDx) assay.


Sep
4
2018

New features in Archer Analysis 6.0

Archer Analysis has been updated to version 6.0, making it more powerful and versatile than ever.


Aug
22
2018

Sensitive and quantitative TP53 variant calling by NGS

The Archer® VariantPlex® p53 Kit combines superior TP53 gene coverage with robust enrichment chemistry and an easy-to-use workflow to give you confident, sensitive and quantitative TP53 variant calling.

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.